Navigation Links
Oncolytics Biotech Inc. Announces 2008 First Quarter Results
Date:4/30/2008

CALGARY, April 30 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced its financial results and highlights for the three month period ended March 31, 2008.

"We are currently enrolling or recruiting patients in a total of nine clinical trials, four exploring the use of REOLYSIN(R) as a monotherapy, and five exploring the use of REOLYSIN(R) in combination with a variety of chemotherapies, immune modulation and radiotherapy," said Dr. Brad Thompson, President and CEO of Oncolytics. "In 2008, we expect to report interim or final results on a number of our ongoing clinical trials. We are rapidly moving toward the point where we can expect to make pivotal clinical trial decisions about REOLYSIN(R). It is an exciting time for Oncolytics and our shareholders."

First Quarter Highlights

Significant Clinical Advances

- Met the criteria to expand to full enrolment of 52 patients in our

U.S. Phase II sarcoma trial after the third patient treated in the

trial experienced stable disease by RECIST criteria for more than

six months.

- In early April, our collaborators presented positive interim results

from our U.K. combination REOLYSIN(R) and paclitaxel/carboplatin

trial at the British Society of Gene Therapy conference in Edinburgh.

Three head and neck patients evaluated to date have had excellent

clinical and radiological responses without appreciable toxicity.

- The U.S. National Cancer Institute filed a protocol with the U.S. FDA

to conduct a Phase I/II ovarian, peritoneal and fallopian tube cancer

trial. The trial is currently recruiting patients.

- Research characterizing immune system responses to REOLYSIN(R) in our

U.K. Phase I systemic administration trial was published in the

March 6 issue of Gene Therapy.

Preclinical Advances

- Tw
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Chips that use light, rather than electricity, to ... and energy efficiency is a growing concern as ... chief components of optical circuits light emitters, ... to build. One promising light source for optical ... optical properties when deposited as a single, atom-thick ...
(Date:9/19/2014)... -- Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology ... to manufacture proteins including biosimilar therapeutics, today announced that ... Annual NewsMakers in the Biotech Industry conference in ... chief executive officer of Pfenex, will provide an overview ... Friday, September 26, 2014 at 10:00 a.m. EDT/7:00 a.m. ...
(Date:9/19/2014)... September 19, 2014 , The ... Society for Paediatric Endocrinology (ESPE) Meeting  Investment ... medical research in the field of growth  , ... Germany , today announced the first ... 2014. The awards were announced during a Satellite Symposium ...
(Date:9/18/2014)... , Sept. 18, 2014 /PRNewswire-iReach/ -- DeepResearchReports.com ... China Acetic Acid Industry" and "2014 Deep Research ... reports to its research database. Photo ... Deep Research Report on Global and China Acetic ... report on China and ...
Breaking Biology Technology:Toward optical chips 2Toward optical chips 3Pfenex to Present at Upcoming Industry Conference on September 26 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 3Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 2Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 3Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 4
... (NYSE AMEX: IBIO ) today announced that it has ... Annual Stockholders Meeting to be held December 8, 2011 at iBio,s ... AM ET. Although only stockholders of record as ... entitled to vote at the meeting, anyone with proof of ownership ...
... materials science and engineering (MSE) researchers have demonstrated ... how energy levels align in a critical group ... breakthrough in the development of sustainable technologies such ... (OLEDs). Transition metal oxides, which are best-known ...
... Nov. 5, 2011 Jennerex, Inc., a private clinical-stage ... of first-in-class targeted oncolytic products for cancer, today presented ... trial of JX-594 in patients with advanced liver cancer ... the high JX-594 dose group versus the low dose ...
Cached Biology Technology:iBio Sets Record Date and Location for December 8 Annual Meeting of Stockholders 2Jennerex Presents Final Data From JX-594 Randomized Phase 2 Clinical Trial Showing Statistically Significant Survival Benefit in Patients With Advanced Liver Cancer 2Jennerex Presents Final Data From JX-594 Randomized Phase 2 Clinical Trial Showing Statistically Significant Survival Benefit in Patients With Advanced Liver Cancer 3Jennerex Presents Final Data From JX-594 Randomized Phase 2 Clinical Trial Showing Statistically Significant Survival Benefit in Patients With Advanced Liver Cancer 4Jennerex Presents Final Data From JX-594 Randomized Phase 2 Clinical Trial Showing Statistically Significant Survival Benefit in Patients With Advanced Liver Cancer 5Jennerex Presents Final Data From JX-594 Randomized Phase 2 Clinical Trial Showing Statistically Significant Survival Benefit in Patients With Advanced Liver Cancer 6
(Date:9/18/2014)... stored in DNA, tiny strands of nucleic acid that ... express this genetic data, our DNA is copied into ... that perform tasks in our cells. , Several ... molecule. Unlike all other known RNAs, this molecule is ... are abundant, little has been known about how they ...
(Date:9/18/2014)... Arizona turned its newborn screening program into a model other ... it the first-ever Newborn Screening Quality Award from the March ... Humble, M.P.H., Arizona,s Department of Health Services director, with the ... a policy of full transparency for the length of time ... the lab for analysis, and set a target of having ...
(Date:9/18/2014)... happy-go-lucky characters, so you might expect that most would ... fact some dogs are distinctly more pessimistic than others, ... "This research is exciting because it measures positive and ... offers researchers and dog owners an insight into the ... Melissa Starling, from the Faculty of Veterinary Science. Her ...
Breaking Biology News(10 mins):Scientists find how mysterious 'circular RNA' is formed, claim muscular dystrophy link 2March of Dimes honors Arizona with first-ever newborn screening award 2March of Dimes honors Arizona with first-ever newborn screening award 3Dogs can be pessimists too 2Dogs can be pessimists too 3
... Health, science and medical reporters are invited to register ... Scientific Meeting March 24 at Moscone Center (North), San ... to focus on the results of care-changing investigations that ... options, advance patient care and improve quality of life. ...
... Seeking to maximise the value of computational modelling ... Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH), ... (PETA) Foundation has produced a free resource for ... on the use of Quantitative Structure Activity Relationships ...
... 2007, a controversial pesticide was approved by the Food and ... in California and Florida. Farm workers and scientists protested the ... is a known carcinogen. Now, MU researchers are studying the ... could be made more efficient and safer for those living ...
Cached Biology News:Media alert: Press registration open for 2012 SIR Annual Scientific Meeting 2PETA launches in silico testing resource to reduce number of animal tests 2MU scientists study how to improve pesticide efficiency 2
... Cell permeable fluorescent minor groove-binding probe ... of double-stranded DNA (preferentially to AT rich ... approximately 20 times greater than DAPI alone. ... ethidium bromide for staining DNA in agarose ...
... The 96 PW is an intelligent full ... washing all wells simultaneously. This instrument gives you ... and outstanding washing efficiency , Performance ... throughput and excellent wash efficiency. A dispense precision ...
... CE 4100 high pressure dual piston pump and ... for added flexibility. The system is ... unit, CE 4901., The CE 4901 PowerStream software ... with Windows 98 and 2000, offers the same ...
...
Biology Products: